
|Videos|July 19, 2023
Rationale for Treatment of MDS With Luspatercept
Author(s)Amy Dezern, MD, MHS
Dr Amy Dezern reviews the mechanism of action of luspatercept and its rationale for use in MDS.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5






































